Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 04.08.2021.

#biopharma
#stockmarket
#COVID19
#genetherapy
#JAFC

Companies And Industries

@biospace shared
On Jul 30, 2021
Three biopharma companies made public debut on @Nasdaq exchange #stockmarket #biopharma https://t.co/GpdfvYug03
Open
Three Biopharma Companies Made Public Debut on Nasdaq Exchange

Three Biopharma Companies Made Public Debut on Nasdaq Exchange

Nuvalent, Rallybio and Icosavax all began selling on the Nasdaq Exchange today. 

@BioWorld shared
On Jul 30, 2021
Japan’s volatile policy direction continues as challenge, but R&D remains strong https://t.co/1Eq5guYkBa
Open
Japan’s volatile policy direction continues as challenge, but R&D remains strong

Japan’s volatile policy direction continues as challenge, but R&D remains strong

Rapid changes, a traditionally conservative approach and a chronic lack of regulatory transparency could undo a lot of the progress that Japan has made in the past few years to speed up ...

@GENbio shared
On Aug 2, 2021
Latest on GEN Edge by @AlexWestchester-- Danaher delivers: @Cytiva and @PallBiotech Plan $1.5B Manufacturing Expansion. Read more: https://t.co/t9nY1bm3td #genetherapy #COVID19 https://t.co/21Dz5EgWtG
Open
Danaher Delivers: Cytiva, Pall Plan $1.5B Manufacturing Expansion

Danaher Delivers: Cytiva, Pall Plan $1.5B Manufacturing Expansion

Biopharma’s ongoing quest to develop COVID-19 drugs and vaccines, plus growing industry demand for producing various types of new therapies, are fueling the $1.5-billion expansion of ...

@FierceBiotech shared
On Jul 30, 2021
Takimoto will join the biotech after coming under Gilead's wing in 2020 through the $4.9 billion acquisition of Forty Seven, where he served as CMO. His most recent role at Gilead was senior vice president, oncology https://t.co/pthXg2h5EQ
Open
IGM poaches Gilead cancer chief Takimoto at pivotal moment for both companies

IGM poaches Gilead cancer chief Takimoto at pivotal moment for both companies

IGM Biosciences has lured away Gilead’s oncology chief Chris Takimoto, M.D., Ph.D., to become chief medical officer, where he will oversee a pipeline of early-stage cancer assets. ...

@FierceBiotech shared
On Jul 30, 2021
Takeda wrapped up the phase 2b trial more than three years ago. Since then, signs of progress on the program have been rare https://t.co/6oPXd6MvCC
Open
Takeda allies with Frazier to spin out late-phase norovirus vaccinei

Takeda allies with Frazier to spin out late-phase norovirus vaccinei

Takeda has spun out its norovirus vaccine prospect to create a biotech: HilleVax. Frazier Healthcare Partners has teamed up with Takeda to found HilleVax, providing investor support for a ...

@eduardoarmienta shared
On Jul 29, 2021
RT @realBioMassSpec: Application of Mass Spectrometry-Based Proteomics to Barley Research #JAFC https://t.co/L6Orj0gLQu
Open
Find my institution

Find my institution

Barley (Hordeum vulgare) is the fourth most cultivated crop in the world in terms of production volume, and it is also the most important raw material of the malting and brewing industries. ...

@FierceBiotech shared
On Jul 30, 2021
Alnylam, which focuses on RNAi therapeutics, has tapped PeptiDream to develop peptide-small interfering RNA (siRNA) conjugates that will help deliver RNAi therapeutics to tissues outside the liver https://t.co/6H5P3lTucw
Open
Another day, another billion-dollar deal for PeptiDream, this time with Alnylam

Another day, another billion-dollar deal for PeptiDream, this time with Alnylam

Apparently a licensing agreement with Takeda worth a potential $3.5 billion wasn’t enough for PeptiDream this week. The biopharmaceutical company, which has a peptide-based drug discovery ...

@FierceBiotech shared
On Jul 30, 2021
Alzheimer's disproportionately affect people of color. Older Black Americans are nearly twice as likely to have the neurodegenerative disease or other dementias and Hispanic Americans are about 1.5 times as likely compared to older white Americans https://t.co/EvndFFIC4M
Open
People of color want to participate in Alzheimer's research. The NIA has a new tool to make it happen

People of color want to participate in Alzheimer's research. The NIA has a new tool to make it happen

The newly approved Alzheimer's disease drug Aduhelm was tested in mostly white individuals, and yet the disease disproportionately impacts people of color. The National Institute on Aging ...